Moderna Inc MRNA
News
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna wins second product approval with RSV vaccine
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
New U.S. bird-flu case is first with respiratory symptoms, CDC says
Moderna's stock climbs on report that bird-flu vaccine funding is near
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to Present at Upcoming Conferences in May/June 2024
Trending: Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
Moderna Announces Update on Investigational RSV Vaccine
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Moderna's stock surges after better-than-expected quarterly results
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign